Climb Bio executives to speak at Wells Fargo healthcare conference fireside chatPUBT·3 hours agoCLYM-1.96%WFC+3.29%
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Rating of "Buy" from AnalystsMarket Beat·Aug 25 at 08:14 AMCLYM-1.96%BLK+0.27%
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy OutlookTip Ranks·Aug 19 at 09:45 AMCLYM-1.96%
Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story?Simplywall·Aug 18 at 11:39 AMCLYM-1.96%
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYMMarket Beat·Aug 16 at 07:29 AMCLYM-1.96%
Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trialPUBT·Aug 14 at 12:33 PMCLYM-1.96%
Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026PUBT·Aug 6 at 11:36 AMCLYM-1.96%
Beyond the Algorithm: What 10 Fringe Stocks Tell Us About the MarketGlobal Report·Jul 28 at 09:13 AMGSUN+0.98%PSX+1.23%
